Baidu
map

Prim Care Diabetes:更年期延迟或可降低T2DM风险

2019-09-11 佚名 国际糖尿病

编者按:绝经是女性必经的一段重要的生理变化,对女性健康具有诸多影响。较早更年期到来与2型糖尿病(T2DM)发病风险增加有关,但更年期年龄与T2DM之间的定量关系尚不清楚。近期来自郑州大学流行病学与卫生统计学研究团队的一篇女性绝经期年龄与2型糖尿病风险相关性荟萃分析揭示了两者之间的联系。该研究发表于Prim Care Diabetes。

编者按:绝经是女性必经的一段重要的生理变化,对女性健康具有诸多影响。较早更年期到来与2型糖尿病(T2DM)发病风险增加有关,但更年期年龄与T2DM之间的定量关系尚不清楚。近期来自郑州大学流行病学与卫生统计学研究团队的一篇女性绝经期年龄与2型糖尿病风险相关性荟萃分析揭示了两者之间的联系。该研究发表于Prim Care Diabetes。

这项荟萃分析纳入了自2019年1月5日前收录于PubMed、Embase和Web of Science等数据库评估更年期年龄和T2DM风险相关性的队列研究,最终其纳入6项研究,共267 284例女性,其中19 654例T2DM患者,平均年龄为56.1~66.9岁,随访时间最长达12.2年。研究结果表明,绝经期最晚年龄组与最早年龄组相比,T2DM发病风险RR为0.64(95% CI:0.44~0.94)。绝经期年龄每增加5岁,T2DM发病风险降低10%(RR=0.90,95% CI:0.84~0.98)(图1)。更年期年龄与T2DM呈负相关(图2)。


图1:更年期每增加5年与2型糖尿病发病相对风险森林图



图2:绝经年龄与2型糖尿病发病风险剂量-反应关系

研究人员评述道“荟萃分析不同于原始研究,可整合分析多项研究,具有更大的样本量,增加了研究结果的可靠性和准确性,并进一步量化了更年期年龄和2型糖尿病之间的剂量反应相关性。”

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1639211, encodeId=dc9e1639211e7, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Dec 01 07:01:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902312, encodeId=aa1119023121a, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Jan 10 10:01:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761196, encodeId=ad021e6119637, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jul 27 20:01:00 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372600, encodeId=cfec3e260062, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Sep 11 21:48:44 CST 2019, time=2019-09-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1639211, encodeId=dc9e1639211e7, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Dec 01 07:01:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902312, encodeId=aa1119023121a, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Jan 10 10:01:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761196, encodeId=ad021e6119637, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jul 27 20:01:00 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372600, encodeId=cfec3e260062, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Sep 11 21:48:44 CST 2019, time=2019-09-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1639211, encodeId=dc9e1639211e7, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Dec 01 07:01:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902312, encodeId=aa1119023121a, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Jan 10 10:01:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761196, encodeId=ad021e6119637, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jul 27 20:01:00 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372600, encodeId=cfec3e260062, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Sep 11 21:48:44 CST 2019, time=2019-09-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1639211, encodeId=dc9e1639211e7, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sun Dec 01 07:01:00 CST 2019, time=2019-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902312, encodeId=aa1119023121a, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Fri Jan 10 10:01:00 CST 2020, time=2020-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761196, encodeId=ad021e6119637, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jul 27 20:01:00 CST 2020, time=2020-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=372600, encodeId=cfec3e260062, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=116, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Sep 11 21:48:44 CST 2019, time=2019-09-11, status=1, ipAttribution=)]
    2019-09-11 医者仁心5538

    学习了

    0

相关资讯

LANCET:确认!这种常见更年期治疗与乳腺癌风险有关

激素治疗是女性更年期常见的干预方式之一,有助于改善女性因激素变化而引起的经期紊乱、潮热出汗、骨质流失、心血管代谢功能变化等。然而,激素治疗是否会增加乳腺癌风险,一直是临床担忧的问题,且证据不一。

ANN ONCOL:更年期激素使用与乳腺癌风险

更年期不同的雌激素和孕激素制剂,治疗方案及使用方式与乳腺癌风险之间的研究尚较少。ANN ONCOL近期发表了一篇文章,评估更年期激素治疗的不同治疗方式与乳腺癌风险之间的关系。

潮热、情绪低落… 应对更年期更有效的治疗方法

女性,52岁,已婚,G2P1。 绝经3年,潮热伴情绪低落2年余。

JAHA:美国研究称,更年期女性雌激素贴片增加心脏外的油

激素替代疗法是治疗更年期相关症状的常用疗法

JCO:认知行为疗法对乳腺癌治疗诱导的更年期症状的疗效

最近,在患有治疗引起的更年期症状的乳腺癌幸存者中,研究人员评估了基于互联网的认知行为疗法(iCBT),无论是否有治疗师支持,对潮热和盗汗(HF / NS),更年期症状的总体水平(主要结果),睡眠质量,HF / NS频率,性功能,心理困扰和与健康相关的生活质量的影响。

出现这四个变化,老爸可能进入更年期了!

父爱如静默的山,父恩如深邃的海,我们吟唱“世上只有妈妈好”,念叨着妈妈更年期的烦恼,却遗忘了壮硕强健的爸爸也会变老,男性也可能深陷更年期的泥沼。让我们与北京协和医院泌尿外科(男性学)李宏军教授一同直面男性更年期,了解父亲,关爱父亲。

Baidu
map
Baidu
map
Baidu
map